Cancer-testis antigen expression in bladder cancer

Progres en Urologie

Volumn 16, Issue 4, 2006, Pages 421-428

  Fradet, Yves ^a   Picard, Valérie ^a   Bergeron, Alain ^a   LaRue, Hélène ^a  

^a LAVAL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

TUMOR ANTIGEN;

ARTICLE; BIOSYNTHESIS; BLADDER TUMOR; CELL CULTURE; HUMAN; MALE; METABOLISM; TUMOR CELL CULTURE; TUMOR CELL LINE;

ANTIGENS, NEOPLASM; CELL LINE, TUMOR; HUMANS; MALE; TUMOR CELLS, CULTURED; URINARY BLADDER NEOPLASMS;

EID: 33750217841     PISSN: 11667087     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. AMLING C.L.: Diagnosis and management of superficial bladder cancer. Curr.Probl.Cancer, 2001; 25: 219-278.
2. BAR-HAIM E., PAZ A., MACHLENKIN A., HAZZAN D., TIROSH B., CARMON L., BRENNER B., VADAI E., MOR O., STEIN A., LEMONNIER F.A., TZEHOVAL E., EISENBACH L.: MAGE-A8 overexpression in transitional cell carcinoma of the bladder: identification of two tumour-associated antigen peptides. Br.J.Cancer, 2004; 91: 398-407.
3. BOEL P., WILDMANN C., SENSI M.L., BRASSEUR R., RENAULD J.C., COULIE P., BOON T., VAN DER BRUGGEN P.: BAGE: a new gene encoding an antigen recognized on human melanomas by cytolytic T lymphocytes. Immunity, 1995; 2: 167-175.
4. CHRISTMAN J.K.: 5-Azacytidine and 5-aza-2′-deoxycytidine as inhibitors of DNA methylation: mechanistic studies and their implications for cancer therapy. Oncogene, 2002; 21: 5483-5495.
5. CORAL S., SIGALOTTI L., ALTOMONTE M., ENGELSBERG A., COLIZZI F., CATTAROSSI I., MARASKOVSKY E., JAGER E., SELIGER B., MAIO M.: 5-aza-2′-deoxycytidine-induced expression of functional cancer testis antigens in human renal cell carcinoma: immunotherapeutic implications. Clin.Cancer Res., 2002; 8: 2690-2695.
6. CORAL S., SIGALOTTI L., GASPAROLLO A., CATTAROSSI I., VISINTIN A., CATTELAN A., ALTOMONTE M., MAIO M.: Prolonged upregulation of the expression of HLA class I antigens and costimulatory molecules on melanoma cells treated with 5-aza-2′-deoxycytidine (5-AZA-CdR). J.Immunother., 1999; 22: 16-24.
7. COULIE P.G., KARANIKAS V., LURQUIN C., COLAU D., CONNEROTTE T., HANAGIRI T., VAN PEL A., LUCAS S., GODELAINE D., LONCHAY C., MARCHAND M., VAN BAREN N., BOON T.: Cytolytic T-cell responses of cancer patients vaccinated with a MAGE antigen. Immunol.Rev., 2002; 188:33-42.
8. GURE A.O., WEI I.J., OLD L.J., CHEN Y.T.: The SSX gene family: characterization of 9 complete genes. Int.J.Cancer, 2002; 101: 448-453.
9. JAGER E., NAGATA Y., GNJATIC S., WADA H., STOCKERT E., KARBACH J., DUNBAR P.R., LEE S.Y., JUNGBLUTH A., JAGER D., ARAND M., RITTER G., CERUNDOLO V., DUPONT B., CHEN Y.T., OLD L.J., KNUTH A.: Monitoring CD8 T cell responses to NY-ESO-1: correlation of humoral and cellular immune responses. Proc.Natl.Acad.Sci.U.S.A, 2000; 97: 4760-4765.
10. JURETIC A., SPAGNOLI G.C., SCHULTZ-THATER E., SARCEVIC B.: Cancer/testis tumour-associated antigens: immunohistochemical detection with monoclonal antibodies. Lancet Oncol., 2003; 4: 104-109.
11. KOCHER T., ZHENG M., BOLLI M., SIMON R., FORSTER T., SCHULTZ-THATER E., REMMEL E., NOPPEN C., SCHMID U., ACKERMANN D., MIHATSCH M.J., GASSER T., HEBERER M., SAUTER G., SPAGNOLI G.C.: Prognostic relevance of MAGE-A4 tumor antigen expression in transitional cell carcinoma of the urinary bladder: a tissue microarray study. Int.J.Cancer, 2002; 100: 702-705.
12. KURASHIGE T., NOGUCHI Y., SAIKA T., ONO T., NAGATA Y., JUNGBLUTH A., RITTER G., CHEN Y.T., STOCKERT E., TSUSHIMA X., KUMON H., OLD L.J., NAKAYAMA E.: NY-ESO-1 expression and immunogenicity associated with transitional cell carcinoma: correlation with tumor grade. Cancer Res., 2001; 61: 4671-4674.
13. LANDRY C., BRASSEUR F., SPAGNOLI G.C., MARBAIX E., BOON T., COULIE P., GODELAINE D.: Monoclonal antibody 57B stains tumor tissues that express gene MAGE-A4. Int.J.Cancer, 2000; 86: 835-841.
14. MARKS P.A., RICHON V.M., BRESLOW R., RIFKIND R.A.: Histone deacetylase inhibitors as new cancer drugs. Curr.Opin.Oncol., 2001; 13: 477-483.
15. PATARD J.J., BRASSEUR F., GIL-DIEZ S., RADVANYI F., MARCHAND M., FRANCOIS P., ABI-AAD A., VAN CANGH P., ABBOU C.C., CHOPIN D.: Expression of MAGE genes in transitional-cell carcinomas of the urinary bladder. Int.J.Cancer, 1995; 64: 60-64.
16. SCANLAN M.J., SIMPSON A.J., OLD L.J.: The cancer/testis genes: review, standardization, and commentary. Cancer Immun., 2004; 4: 1
17. SHARMA P., GNJATIC S., JUNGBLUTH A.A., WILLIAMSON B., HERR H., STOCKERT E., DALBAGNI G., DONAT S.M., REUTER V.E., SANTIAGO D., CHEN Y.T., BAJORIN D.F., OLD L.J.: Frequency of NY-ESO-1 and LAGE-1 expression in bladder cancer and evidence of a new NY-ESO-1 T-cell epitope in a patient with bladder cancer. Cancer Immun., 2003; 3: 19
18. STOCKERT E., JAGER E., CHEN Y.T., SCANLAN M.J., GOUT I., KARBACH J., ARAND M., KNUTH A., OLD L.J.: A survey of the humoral immune response of cancer patients to a panel of human tumor antigens. J.Exp.Med., 1998; 187: 1349-1354.
19. ZENDMAN A.J., RUITER D.J., VAN MUIJEN G.N.: Cancer/testis-associated genes: identification, expression profile, and putative function. J.Cell Physiol, 2003; 194: 272-288.